Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 31, 2006 Brian Gorman	Novartis Gets Its Way FDA approval for Omnitrope suggests Novartis has a bright future in biogenerics, and that's good news for the company's investors.
The Motley Fool July 29, 2010 Brian Orelli	Buy, Sell, or Hold: Biotech Generics Generic biotech drugs are coming. Hop on.
The Motley Fool October 26, 2007 Brian Orelli	Investing in Follow-On Biologics Investors, while approvals of follow-on biologics in the U.S. are probably still years away, now is the time to do your research. Those that are leading the race overseas are likely to be first in line when the FDA opens its door to applications.
The Motley Fool November 20, 2006 Brian Gorman	Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The Motley Fool July 18, 2011 Brian Orelli	A $3.6 Billion Franchise at Stake Amgen and Teva settle their patent dispute, and Amgen investors have a little better idea of when the company's $3.6 billion Neupogen and Neulasta franchise might come under attack in the United States.
The Motley Fool June 30, 2009 Brian Orelli	Following the Pack to Future Returns Mylan's playing catch up, but there's room for more.
The Motley Fool October 3, 2008 Brian Orelli	Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche.
The Motley Fool February 22, 2011 Brian Orelli	A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool December 20, 2011 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Amgen Goes Generic Biosimilars are coming -- might as well get a piece of the action.
The Motley Fool June 11, 2009 Brian Orelli	The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics.
The Motley Fool February 25, 2008 Brian Orelli	Look Across the Pond for Biosimilars Teva, ratiopharm, and CT Arzneimittel all get positive recommendations for their new biosimilars, as approvals for generic equivalents to biotech drugs are heating up in Europe.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool January 5, 2011 Brian Orelli	Spectrum Pharma Jumps in With the Big Dogs Spectrum is developing biosimilars.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
The Motley Fool January 21, 2009 Brian Orelli	A Copycat on the Prowl Teva Pharmaceutical announces it is partnering with Lonza to develop generic versions of biologics, called biosimilars, or follow-on biologics.
The Motley Fool August 31, 2007 Brian Lawler	Novartis on the Biosimilar Attack Novartis received final marketing approval today for only the second biosimilar product ever to gain a regulatory OK in the European Union. The EU market welcomes the drugmaker's copy of a treatment for anemia.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool January 23, 2008 Brian Orelli	Teva Buys In to Biologics Teva Pharmaceutical announces that it was acquiring privately held CoGenesys, for $400 million in cash.
The Motley Fool April 17, 2006 Brian Gorman	Novartis Presses on Biogenerics The company wins a court case that could accelerate U.S. regulations for biogenerics. Recent developments suggest Novartis' strategy may be close to paying off. Investors, take note.
Pharmaceutical Executive January 21, 2014 Ben Comer	Biosimilars or Bust Will biosimimilars make much of an impact on drug cost?
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
Pharmaceutical Executive February 1, 2006 Sarah Houlton	Global Report: Moving Towards Generic Biologics The European Medicines Agency hopes to complete its guidelines for the approval of biosimilar drugs early this year, paving the way for the approval of biogenerics - and a potential goldmine for the generics companies.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
The Motley Fool November 7, 2008 Brian Orelli	Will Obama Make Your Portfolio Healthy? The changes coming in the health-care industry could be a mixed bag of good and bad for your portfolio.
The Motley Fool June 22, 2007 Brian Lawler	Novartis' Good Week The pharma receives a pair of positive regulatory decisions. Investors, take note.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool February 13, 2009 Brian Orelli	The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool December 2, 2009 Brian Orelli	Tired of Waiting, Teva Advances Teva Pharmaceutical decides it's not worth waiting for the U.S. government to establish a pathway for approval of generic versions of biologic drugs. Instead, it's asking for approval for its copycat of Amgen's Neupogen under the normal branded-drug process.
Chemistry World July 2, 2013 Phillip Broadwith	Biosimilar drugs step up complexity The first ever generic monoclonal antibody therapies have been recommended for approval in Europe.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool May 15, 2008 Brian Orelli	Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
The Motley Fool November 21, 2007 Brian Orelli	Black Friday Bargain Stock: Dr. Reddy's Laboratories Is Dr. Reddy's Laboratories a good value right now? Growth is slowing at the generic drugmaker, but is it enough to justify the drop in price?
Pharmaceutical Executive September 1, 2011 Jill B. Conner	Complex Biologics: The View from Teva Industry and regulators alike must grapple with the sensitivities associated with developing bio-similar drugs.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
Chemistry World January 9, 2015 Rebecca Trager	US poised to approve its first 'biosimilar' drug A key committee of the US Food and Drug Administration has voted in favor of licensing a copycat version of a biological drug. If approved, Sandoz's Zarxio (filgrastim) would be the first 'biosimilar' drug available in the US.
The Motley Fool December 18, 2009 Brian Orelli	Buy a Company, Get the Plant for Free Earlier this year, Merck company bought a pipeline of follow-on biologics (and a manufacturing plant to make them in) from Insmed. Now it's back for more with an acquisition of Avecia Biologics.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool August 30, 2006 Brian Gorman	Mylan's Biogeneric Play The generic drugmaker buys an Indian firm to strengthen its long-term prospects. Investors, take note.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.